½ÃÀ庸°í¼­
»óǰÄÚµå
1620752

ÀüÀÓ»ó À̹Ì¡ ½ÃÀå : Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Preclinical Imaging Market by Product (Modalities, Reagents), Application (Drug Discovery, Research & Development), End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 181 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀüÀÓ»ó À̹Ì¡ ½ÃÀåÀº 2023³â¿¡ 24¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 26¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 4.91%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 34¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÓ»ó Àü À̹Ì¡Àº ÀǾàǰ °³¹ß °úÁ¤¿¡¼­ ÇʼöÀûÀÎ ¿ä¼Ò·Î, Áúº´ ¸ðµ¨ ¿¬±¸, ÀǾàǰ Èĺ¸¹°ÁúÀÇ È¿´É Æò°¡, »ýü ³» »ý¹°ÇÐÀû °úÁ¤ ÀÌÇØ¿¡ ÀÚÁÖ »ç¿ëµË´Ï´Ù. ±× ¹üÀ§´Â MRI, PET, CT, ±¤ÇÐ, ÃÊÀ½ÆÄ µî ´Ù¾çÇÑ ¿µ»ó ¾ç½ÄÀ» Æ÷ÇÔÇϸç, Áß°³¿¬±¸¿¡ ÇʼöÀûÀÎ »ó¼¼ÇÑ °ø°£Àû, ½Ã°£Àû µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù. ÀüÀÓ»ó À̹Ì¡ÀÇ Çʿ伺Àº µ¿¹° ¸ðµ¨À» ¿¬±¸ÇÒ ¼ö ÀÖ´Â ³ôÀº 󸮷®°ú Á¤·®È­ °¡´ÉÇÑ ºñħ½ÀÀû µµ±¸¸¦ Á¦°øÇÔÀ¸·Î½á ½Å¾à °³¹ß °úÁ¤À» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ´Â ´É·Â¿¡ ÀÖ½À´Ï´Ù. ÁÖ·Î Á¾¾çÇÐ, ½Å°æÇÐ, ½ÉÀåÇÐ, °¨¿°Çп¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 24¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 26¾ï ´Þ·¯
¿¹Ãø³â(2030) 34¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 4.91%

ÀÓ»ó Àü À̹Ì¡ ½ÃÀå °³Ã´Àº ÁÖ·Î À̹Ì¡ ±â¼úÀÇ ¹ßÀü, R&D ÅõÀÚ Áõ°¡, È¿°úÀûÀÎ ÀǾàǰ °³¹ßÀÌ ÇÊ¿äÇÑ ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ºÐÀÚ À̹Ì¡°ú À̹ÌÁö ºÐ¼® ¹× ÇØ¼®À» °­È­Çϱâ À§ÇÑ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕ¿¡ »õ·Î¿î ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. ½ÃÀå °ü°èÀڵ鿡 ´ëÇÑ Á¦¾ÈÇÒ ¼ö ÀÖ´Â °ÍÀº Çмú ¿¬±¸ ±â°ü°úÀÇ °øµ¿ ÇÁ·ÎÁ§Æ®¿¡ ÁýÁßÇϰí, À̹ÌÁö ºÐ¼® ¼­ºñ½º Á¦°øÀ» È®´ëÇÏ´Â °ÍÀÔ´Ï´Ù. ±×·¯³ª ³ôÀº Àåºñ ¹× À¯Áöº¸¼ö ºñ¿ë, ±ÔÁ¦ À庮, µ¿¹° ½ÇÇè¿¡ ´ëÇÑ À±¸®Àû °í·Á µî ¿©ÀüÈ÷ ³²¾Æ ÀÖ´Â ¹®Á¦µéÀÌ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

±â¼ú Çõ½Å Ãø¸é¿¡¼­ ºñ¿ë È¿À²ÀûÀÎ À̹Ì¡ ±â¼ú °³¹ß°ú À̹ÌÁö ÇØ»óµµ Çâ»óÀÌ ÁÖ¿ä ¿¬±¸ ºÐ¾ßÀÔ´Ï´Ù. ¶ÇÇÑ, À̹Ì¡ ½Ã½ºÅÛÀÇ ¼ÒÇüÈ­ ¹× ¸ÖƼ¸ð´Þ À̹Ì¡ ¼Ö·ç¼ÇÀÇ Ã¤Åà °¡´É¼ºµµ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀüÀÓ»ó À̹Ì¡ÀÌ ¹ÙÀÌ¿À¸¶Ä¿ ½Äº° ¹× Ä¡·á¹ý ¸ÂÃãÈ­¿¡ Å©°Ô ±â¿©ÇÒ ¼ö ÀÖ´Â °³ÀθÂÃãÇü ÀÇ·á ºÐ¾ß¿¡¼­µµ ºñÁî´Ï½º ±âȸ°¡ ÀÖ½À´Ï´Ù. ÀüÀÓ»ó À̹Ì¡ ½ÃÀåÀº ¿ªµ¿ÀûÀÌ°í °æÀïÀÌ Ä¡¿­Çϸç, ±â¼ú ¹ßÀüÀÌ Â÷º°È­ÀÇ Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌÇØ°ü°èÀÚµéÀº Áö¼ÓÀûÀÎ ¼ºÀåÀ» À§ÇØ »õ·Î¿î Æ®·»µå¸¦ È¿°úÀûÀ¸·Î Ȱ¿ëÇϱâ À§ÇØ Ãֽбâ¼ú Çõ½Å°ú ±ÔÁ¦ ÇöȲÀ» Áö¼ÓÀûÀ¸·Î ÆÄ¾ÇÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ÀüÀÓ»ó À̹Ì¡ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀÓ»ó Àü À̹Ì¡ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Á¦¾à±â¾÷ÀÇ R&D Ȱµ¿ Ȱ¼ºÈ­
    • »ý¹°ÀÇÇÐ ¿¬±¸ È®´ë¸¦ À§ÇÑ Á¤ºÎ ÅõÀÚ ¹× ÀÚ±Ý Áö¿ø Áõ°¡
    • Àӻ󿬱¸±â°ü(CRO) Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¿µ»óÁø´Ü±â±â ¹× ÀüÀÓ»ó ¿µ»óÀåºñÀÇ À¯Áöº¸¼ö ºñ¿ë ±ÞÁõ
  • ½ÃÀå ±âȸ
    • ¿µ»ó ºÐ¼®À» °³¼±Çϱâ À§ÇØ ÀüÀÓ»ó ¿µ»ó¿¡ ÷´Ü ±â¼ú žÀç Áõ°¡
    • ¸ÂÃãÇü ÀÇ·á °³¹ß¿¡ ´ëÇÑ °ü½É Áõ°¡
  • ½ÃÀå °úÁ¦
    • µ¿¹° ½ÇÇè°ú °ü·ÃµÈ ¾ö°ÝÇÑ ±ÔÁ¦¿Í À±¸®Àû ¹®Á¦

Porter's Five Forces: ÀüÀÓ»ó À̹Ì¡ ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀüÀÓ»ó À̹Ì¡ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

PESTLE ºÐ¼® : ÀüÀÓ»ó À̹Ì¡ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀüÀÓ»ó À̹Ì¡ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀüÀÓ»ó À̹Ì¡ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

ÀüÀÓ»ó À̹Ì¡ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÀüÀÓ»ó À̹Ì¡ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀüÀÓ»ó À̹Ì¡ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ÀüÀÓ»ó À̹Ì¡ ½ÃÀå¿¡¼­ÀÇ ¼º°øÀ» À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ

ÀüÀÓ»ó À̹Ì¡ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
    • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
      • Á¤Ä¡Àû
      • °æÁ¦Àû
      • »çȸÀû
      • ±â¼úÀû
      • ¹ýÀû
      • ȯ°æÀû

    Á¦6Àå ÀüÀÓ»ó À̹Ì¡ ½ÃÀå : Á¦Ç°º°

    • ¸ð´Þ¸®Æ¼
      • ÀÚ¼º ÀÔÀÚ À̹Ì¡
      • Àڱ⠰ø¸í È­»ó
      • ¸¶ÀÌÅ©·Î ÄÄÇ»ÅÍ ´ÜÃþ ÃÔ¿µ
      • ±¤ÇÐ À̹Ì¡
      • ¾çÀüÀÚ ¹æÃâ ´ÜÃþ ÃÔ¿µ
      • ´ÜÀÏ ±¤ÀÚ ¹æÃâ ÄÄÇ»ÅÍ ´ÜÃþ ÃÔ¿µ
    • ½Ã¾à
      • »ý¹° ¹ß±¤ À̹Ì¡ ½Ã¾à
      • Çü±¤ À̹Ì¡ ½Ã¾à
      • MRI Á¶¿µÁ¦
      • PET ¹æ»ç¼º Æ®·¹À̼­
      • ÃÊÀ½ÆÄ Á¶¿µÁ¦
      • X¼± CT Á¶¿µÁ¦

    Á¦7Àå ÀüÀÓ»ó À̹Ì¡ ½ÃÀå : ¿ëµµº°

    • â¾à
    • ¿¬±¸°³¹ß

    Á¦8Àå ÀüÀÓ»ó À̹Ì¡ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

    • Çмú±â°ü ¹× Á¤ºÎ¿¬±¸±â°ü
    • °è¾à¿¬±¸±â°ü(CRO)
    • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

    Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀüÀÓ»ó À̹Ì¡ ½ÃÀå

    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • ¹Ì±¹

    Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀüÀÓ»ó À̹Ì¡ ½ÃÀå

    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • Àεµ³×½Ã¾Æ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Çʸ®ÇÉ
    • ½Ì°¡Æ÷¸£
    • Çѱ¹
    • ´ë¸¸
    • ű¹
    • º£Æ®³²

    Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀüÀÓ»ó À̹Ì¡ ½ÃÀå

    • µ§¸¶Å©
    • ÀÌÁýÆ®
    • Çɶõµå
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • À̽º¶ó¿¤
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ³ªÀÌÁö¸®¾Æ
    • ³ë¸£¿þÀÌ
    • Æú¶õµå
    • īŸ¸£
    • ·¯½Ã¾Æ
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ½ºÀ§½º
    • ÅÍŰ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¿µ±¹

    Á¦12Àå °æÀï ±¸µµ

    • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
    • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
    • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Àü·« ºÐ¼®°ú Á¦¾È

    ±â¾÷ ¸ñ·Ï

    • Advanced Molecular Vision, Inc.
    • Angstrom Advanced Inc.
    • Aspect Imaging Ltd.
    • Berthold Technologies
    • Bruker Corporation
    • Euro-BioImaging ERIC
    • FUJIFILM Holdings America Corporation
    • IVIM Technology Corp.
    • KUBTEC Technology
    • LI-COR, Inc.
    • Mediso Ltd.
    • Milabs BV
    • Miltenyi Biotec GmbH
    • MR Solutions Group
    • Peira bvba
    • PerkinElmer Inc.
    • Revvity, Inc.
    • Scitech Pty Ltd.
    • United Imaging Healthcare Co., Ltd.
    BJH 25.01.08

    The Preclinical Imaging Market was valued at USD 2.48 billion in 2023, expected to reach USD 2.60 billion in 2024, and is projected to grow at a CAGR of 4.91%, to USD 3.48 billion by 2030.

    Preclinical imaging is an essential component of the drug development process, often used to study disease models, evaluate drug candidate efficacy, and understand biological processes in vivo. Its scope includes various imaging modalities such as MRI, PET, CT, optical, and ultrasound, providing detailed spatial and temporal data crucial for translational research. The necessity of preclinical imaging lies in its ability to accelerate the drug discovery process by offering high-throughput, quantifiable, non-invasive tools for studying animal models. It is applied across pharmaceutical, biotechnology, and research institutions, primarily serving applications in oncology, neurology, cardiology, and infectious diseases.

    KEY MARKET STATISTICS
    Base Year [2023] USD 2.48 billion
    Estimated Year [2024] USD 2.60 billion
    Forecast Year [2030] USD 3.48 billion
    CAGR (%) 4.91%

    The market growth of preclinical imaging is primarily influenced by advancements in imaging technology, increased investment in R&D, and the rising prevalence of chronic diseases necessitating effective drug development. Emerging opportunities exist in molecular imaging and the integration of AI and machine learning to enhance image analysis and interpretation. Recommendations for market players include focusing on collaborative projects with academic and research institutions and expanding service offerings in image analysis. However, challenges persist, including high costs of equipment and maintenance, regulatory hurdles, and the ethical considerations surrounding animal testing, which could potentially hinder market growth.

    In terms of innovation, developing cost-effective imaging technologies and enhancing imaging resolution are prime areas of research. Additionally, there is potential in the miniaturization of imaging systems and the adoption of multi-modal imaging solutions. Businesses can also explore opportunities in personalized medicine, wherein preclinical imaging can significantly contribute to identifying biomarkers and tailoring treatments. The preclinical imaging market exhibits a dynamic and competitive nature, with technological advancements being a key driver for differentiation. Stakeholders must stay abreast of the latest innovations and regulatory landscapes to effectively leverage emerging trends for sustained growth.

    Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preclinical Imaging Market

    The Preclinical Imaging Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

    • Market Drivers
      • Increasing research & development activities by pharmaceutical companies
      • Growing government investment and funding for expanding biomedical research
      • Rising number of clinical research organizations (CROs)
    • Market Restraints
      • High cost of imaging equipment and maintenance of preclinical imaging
    • Market Opportunities
      • Increasing incorporation of advanced technologies in preclinical imaging to improve image analysis
      • Rising focus on the development of personalized medicines
    • Market Challenges
      • Strict regulations and ethical concerns associated with animal research

    Porter's Five Forces: A Strategic Tool for Navigating the Preclinical Imaging Market

    Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preclinical Imaging Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

    PESTLE Analysis: Navigating External Influences in the Preclinical Imaging Market

    External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preclinical Imaging Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

    Market Share Analysis: Understanding the Competitive Landscape in the Preclinical Imaging Market

    A detailed market share analysis in the Preclinical Imaging Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

    FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preclinical Imaging Market

    The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preclinical Imaging Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

    Strategy Analysis & Recommendation: Charting a Path to Success in the Preclinical Imaging Market

    A strategic analysis of the Preclinical Imaging Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

    Key Company Profiles

    The report delves into recent significant developments in the Preclinical Imaging Market, highlighting leading vendors and their innovative profiles. These include Advanced Molecular Vision, Inc., Angstrom Advanced Inc., Aspect Imaging Ltd., Berthold Technologies, Bruker Corporation, Euro-BioImaging ERIC, FUJIFILM Holdings America Corporation, IVIM Technology Corp., KUBTEC Technology, LI-COR, Inc., Mediso Ltd., Milabs BV, Miltenyi Biotec GmbH, MR Solutions Group, Peira bvba, PerkinElmer Inc., Revvity, Inc., Scitech Pty Ltd., and United Imaging Healthcare Co., Ltd..

    Market Segmentation & Coverage

    This research report categorizes the Preclinical Imaging Market to forecast the revenues and analyze trends in each of the following sub-markets:

    • Based on Product, market is studied across Modalities and Reagents. The Modalities is further studied across Magnetic Particle Imaging, Magnetic Resonance Imaging, Micro-Computed Tomography, Optical Imaging, Positron Emission Tomography, and Single-Photon Emission Computed Tomography. The Reagents is further studied across Bioluminescent Imaging Reagents, Fluorescent Imaging Reagents, MRI Contrasting Reagents, PET Radioactive Tracers, Ultrasound Contrasting Reagents, and X-ray CT Contrasting Reagents.
    • Based on Application, market is studied across Drug Discovery and Research & Development.
    • Based on End-User, market is studied across Academic & Government Research Institutes, Contract Research Organizations (CROs), and Pharmaceutical & Biotechnology Companies.
    • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

    The report offers a comprehensive analysis of the market, covering key focus areas:

    1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

    2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

    3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

    4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

    5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

    The report also answers critical questions to aid stakeholders in making informed decisions:

    1. What is the current market size, and what is the forecasted growth?

    2. Which products, segments, and regions offer the best investment opportunities?

    3. What are the key technology trends and regulatory influences shaping the market?

    4. How do leading vendors rank in terms of market share and competitive positioning?

    5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

    Table of Contents

    1. Preface

    • 1.1. Objectives of the Study
    • 1.2. Market Segmentation & Coverage
    • 1.3. Years Considered for the Study
    • 1.4. Currency & Pricing
    • 1.5. Language
    • 1.6. Stakeholders

    2. Research Methodology

    • 2.1. Define: Research Objective
    • 2.2. Determine: Research Design
    • 2.3. Prepare: Research Instrument
    • 2.4. Collect: Data Source
    • 2.5. Analyze: Data Interpretation
    • 2.6. Formulate: Data Verification
    • 2.7. Publish: Research Report
    • 2.8. Repeat: Report Update

    3. Executive Summary

    4. Market Overview

    5. Market Insights

    • 5.1. Market Dynamics
      • 5.1.1. Drivers
        • 5.1.1.1. Increasing research & development activities by pharmaceutical companies
        • 5.1.1.2. Growing government investment and funding for expanding biomedical research
        • 5.1.1.3. Rising number of clinical research organizations (CROs)
      • 5.1.2. Restraints
        • 5.1.2.1. High cost of imaging equipment and maintenance of preclinical imaging
      • 5.1.3. Opportunities
        • 5.1.3.1. Increasing incorporation of advanced technologies in preclinical imaging to improve image analysis
        • 5.1.3.2. Rising focus on the development of personalized medicines
      • 5.1.4. Challenges
        • 5.1.4.1. Strict regulations and ethical concerns associated with animal research
    • 5.2. Market Segmentation Analysis
      • 5.2.1. Product: Growing usage of modalities in preclinical studies for specific research needs
      • 5.2.2. End-User: Increasing adoption of preclinical imaging by pharmaceutical & biopharmaceutical companies to develop new drugs
    • 5.3. Porter's Five Forces Analysis
      • 5.3.1. Threat of New Entrants
      • 5.3.2. Threat of Substitutes
      • 5.3.3. Bargaining Power of Customers
      • 5.3.4. Bargaining Power of Suppliers
      • 5.3.5. Industry Rivalry
    • 5.4. PESTLE Analysis
      • 5.4.1. Political
      • 5.4.2. Economic
      • 5.4.3. Social
      • 5.4.4. Technological
      • 5.4.5. Legal
      • 5.4.6. Environmental

    6. Preclinical Imaging Market, by Product

    • 6.1. Introduction
    • 6.2. Modalities
      • 6.2.1. Magnetic Particle Imaging
      • 6.2.2. Magnetic Resonance Imaging
      • 6.2.3. Micro-Computed Tomography
      • 6.2.4. Optical Imaging
      • 6.2.5. Positron Emission Tomography
      • 6.2.6. Single-Photon Emission Computed Tomography
    • 6.3. Reagents
      • 6.3.1. Bioluminescent Imaging Reagents
      • 6.3.2. Fluorescent Imaging Reagents
      • 6.3.3. MRI Contrasting Reagents
      • 6.3.4. PET Radioactive Tracers
      • 6.3.5. Ultrasound Contrasting Reagents
      • 6.3.6. X-ray CT Contrasting Reagents

    7. Preclinical Imaging Market, by Application

    • 7.1. Introduction
    • 7.2. Drug Discovery
    • 7.3. Research & Development

    8. Preclinical Imaging Market, by End-User

    • 8.1. Introduction
    • 8.2. Academic & Government Research Institutes
    • 8.3. Contract Research Organizations (CROs)
    • 8.4. Pharmaceutical & Biotechnology Companies

    9. Americas Preclinical Imaging Market

    • 9.1. Introduction
    • 9.2. Argentina
    • 9.3. Brazil
    • 9.4. Canada
    • 9.5. Mexico
    • 9.6. United States

    10. Asia-Pacific Preclinical Imaging Market

    • 10.1. Introduction
    • 10.2. Australia
    • 10.3. China
    • 10.4. India
    • 10.5. Indonesia
    • 10.6. Japan
    • 10.7. Malaysia
    • 10.8. Philippines
    • 10.9. Singapore
    • 10.10. South Korea
    • 10.11. Taiwan
    • 10.12. Thailand
    • 10.13. Vietnam

    11. Europe, Middle East & Africa Preclinical Imaging Market

    • 11.1. Introduction
    • 11.2. Denmark
    • 11.3. Egypt
    • 11.4. Finland
    • 11.5. France
    • 11.6. Germany
    • 11.7. Israel
    • 11.8. Italy
    • 11.9. Netherlands
    • 11.10. Nigeria
    • 11.11. Norway
    • 11.12. Poland
    • 11.13. Qatar
    • 11.14. Russia
    • 11.15. Saudi Arabia
    • 11.16. South Africa
    • 11.17. Spain
    • 11.18. Sweden
    • 11.19. Switzerland
    • 11.20. Turkey
    • 11.21. United Arab Emirates
    • 11.22. United Kingdom

    12. Competitive Landscape

    • 12.1. Market Share Analysis, 2023
    • 12.2. FPNV Positioning Matrix, 2023
    • 12.3. Competitive Scenario Analysis
      • 12.3.1. Revvity, Inc.'s Innovative Preclinical Imaging Solutions Unveiled at WMIC 2023
    • 12.4. Strategy Analysis & Recommendation

    Companies Mentioned

    • 1. Advanced Molecular Vision, Inc.
    • 2. Angstrom Advanced Inc.
    • 3. Aspect Imaging Ltd.
    • 4. Berthold Technologies
    • 5. Bruker Corporation
    • 6. Euro-BioImaging ERIC
    • 7. FUJIFILM Holdings America Corporation
    • 8. IVIM Technology Corp.
    • 9. KUBTEC Technology
    • 10. LI-COR, Inc.
    • 11. Mediso Ltd.
    • 12. Milabs BV
    • 13. Miltenyi Biotec GmbH
    • 14. MR Solutions Group
    • 15. Peira bvba
    • 16. PerkinElmer Inc.
    • 17. Revvity, Inc.
    • 18. Scitech Pty Ltd.
    • 19. United Imaging Healthcare Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦